Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPTR-147 Monotherapy and with Pembrolizumab in Solid Tumors and Lymphomas
NCT03815682Phase 1Terminated
- Sponsor
- Repertoire Immune Medicines
- Start
- Oct 2018
- Primary completion
- Sep 2022
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of RPTR-147 in solid tumor and lymphoma (3 arms), sponsored by Repertoire Immune Medicines. Primary endpoints: Dose Limiting Toxicities and Frequency of Dose Interruptions. Started Oct 2018; status: terminated.
02
Drugs
RPTR-147
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT03815682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03815682.